Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Similarity of ABP 206 vs Nivolumab in Resected Melanoma (Adjuvant)
jRCT2031230360Active, not recruiting
- Sponsor
- Amgen
- Start
- Apr 2024
- Modality
- Device-based Delivery → Drug Delivery Systems
01
Overview
Randomised, double-blind trial of ABP 206 in melanoma (3 arms), sponsored by Amgen. Primary endpoints: AUC0-28d and AUCtau_SS. Started Apr 2024; status: active, not recruiting.
02
Drugs
ABP 206
03
Conditions
melanoma
Beyond the preview
Go deeper on jRCT2031230360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230360.